Literature DB >> 30925138

Low-Dose Radiation Promotes the Proliferation and Migration of AGE-Treated Endothelial Progenitor Cells Derived from Bone Marrow via Activating SDF-1/CXCR4/ERK Signaling Pathway.

Ping Wang1, Haifeng Zhang2, Zhuo Li3, Xiaobo Liu1, Yingli Jin4, Manman Lei3, Zixuan Jiao3, Yaru Bi3, Weiying Guo3.   

Abstract

Low-dose radiation (LDR) has been confirmed to mobilize bone marrow-derived endothelial progenitor cells (EPCs) and promote diabetic wound healing. But it is unclear whether LDR acts directly on EPCs and promotes their proliferation and migration. Given the key role of advanced glycosylation end products (AGE) in the pathogenesis of diabetes, we used AGE to induce EPC damage. We then investigated the effect of LDR on the proliferation and migration of AGE-treated EPCs and explored the underlying mechanisms. EPCs cultured in vitro were treated with different concentrations of AGE, and the cells were then exposed to different low doses and treated with a specific antagonist for CXCR4, AMD3100 (1 lmol/l). The proliferation and migration abilities of EPCs were detected using the CCK-8 and wound healing assays, respectively. The mRNA and protein expression of SDF-1 and CXCR4 in AGE-treated EPCs were measured using qPCR and Western blot analysis, respectively. The expressions of ERK and phosphorylated ERK (pERK) were detected using Western blot analysis. The results showed that 200 mg/l and 400 mg/l AGE had an inhibitory effect on the proliferation of EPCs, and this inhibitory effect was exerted in a dose- and time-dependent manner. AGE significantly reduced the migration ability of EPCs cultured in vitro. After the cells received either 50 or 75 mGy low-dose irradiation, the proliferation of EPCs and AGE-treated EPCs was clearly increased; in addition, LDR also enhanced cell migration ability, but this enhancement was counteracted by AMD3100. Results from qPCR and Western blot analysis showed that LDR increased the mRNA and protein expression of SDF-1/ CXCR4. LDR also upregulated pERK expression in EPCs and AGE-treated EPCs, but LDR-induced upregulation of pERK expression was inhibited by AMD3100. These findings indicate that LDR can directly activate the SDF-1/CXCR4 biological axis and downstream ERK signaling pathway, and promote the proliferation and migration abilities of EPCs by increasing the expression of SDF-1, CXCR4 and pERK in EPCs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30925138     DOI: 10.1667/RR15200.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  5 in total

Review 1.  The Impact of Advanced Glycation End-Products (AGEs) on Proliferation and Apoptosis of Primary Stem Cells: A Systematic Review.

Authors:  Lize Evens; Hanne Beliën; Dorien Deluyker; Annelies Bronckaers; Pascal Gervois; Marc Hendrikx; Virginie Bito
Journal:  Stem Cells Int       Date:  2020-11-14       Impact factor: 5.443

2.  Role of the stromal cell derived factor-1 in the biological functions of endothelial progenitor cells and its underlying mechanisms.

Authors:  Yanping Cun; Bo Diao; Zhimin Zhang; Gang Wang; Jing Yu; Lianting Ma; Zhiguo Rao
Journal:  Exp Ther Med       Date:  2020-11-17       Impact factor: 2.447

3.  WNT16B enhances the proliferation and self-renewal of limbal epithelial cells via CXCR4/MEK/ERK signaling.

Authors:  Songjiao Zhao; Xichen Wan; Yiqin Dai; Lan Gong; Qihua Le
Journal:  Stem Cell Reports       Date:  2022-03-31       Impact factor: 7.294

4.  Shear stress improves the endothelial progenitor cell function via the CXCR7/ERK pathway axis in the coronary artery disease cases.

Authors:  Hua Zhou; Qiang Tu; Yan Zhang; Hua Qiang Xie; Qing Yun Shuai; Xiao Chuan Huang; Jie Fu; Zheng Cao
Journal:  BMC Cardiovasc Disord       Date:  2020-09-07       Impact factor: 2.298

5.  Experimental Study on the Effect of Allogeneic Endothelial Progenitor Cells on Wound Healing in Diabetic Mice.

Authors:  Min Leng; Ying Peng; Manchang Pan; Hong Wang
Journal:  J Diabetes Res       Date:  2021-10-21       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.